Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other solid neoplasm 1Lymphoid 1

Conditions

Solid Tumor Cancer 1Lymphoma, Non-Hodgkin 1Hodgkin Disease 1

Interventions

Paclitaxel 490Carboplatin 436Gemcitabine 394Docetaxel 385Cisplatin 360pembrolizumab 344Bevacizumab 335Nivolumab 261Pemetrexed 243Capecitabine 221Dexamethasone 213Fluorouracil 211Rituximab 203Trastuzumab 193Cyclophosphamide 190Oxaliplatin 160Erlotinib Hydrochloride 147Ipilimumab 145atezolizumab 144Prednisone 144Cetuximab 142Irinotecan 139Leucovorin 130Doxorubicin 130Sorafenib 120Lenalidomide 119Bortezomib 118Sunitinib 107Everolimus 93130-nm albumin-bound paclitaxel 92

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × INDUSTRY × SB 743921 × Clear all
NCT00343564 2020-01-13

A Study of SB-743921 in Non-Hodgkin Lymphoma and Hodgkin Lymphoma

Cytokinetics

Phase 1/2 Completed
68 enrolled 26 charts
Lymphoid

Hodgkin Disease, Lymphoma, Non-Hodgkin

NCT00136513 2008-10-16

SB-743921 In Patients With Solid Tumors

GlaxoSmithKline

Phase 1 Completed
30 enrolled
Other solid neoplasm

Solid Tumor Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡